{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:57:53Z","timestamp":1790305073054,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajt.2026.07.031","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:21:40Z","timestamp":1785885700000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond trough levels: Tacrolimus dose requirements and individualized monitoring in kidney transplantation"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6345-6206","authenticated-orcid":false,"given":"Stefan","family":"Reuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-9680","authenticated-orcid":false,"given":"Dirk R.J.","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajt.2026.07.031_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.ajt.2026.07.031_bib2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/ajt.12191","article-title":"Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials","volume":"13","author":"Bouamar","year":"2013","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2026.07.031_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"St\u00f8rset","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.ajt.2026.07.031_bib4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003088-200443110-00005","article-title":"Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal allograft recipients","volume":"43","author":"Kuypers","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.ajt.2026.07.031_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111128","article-title":"The tacrolimus metabolism rate influences renal function after kidney transplantation","volume":"9","author":"Th\u00f6lking","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ajt.2026.07.031_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajt.2026.07.031_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.ajt.2026.07.031_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/01.TP.0000151766.73249.12","article-title":"Tacrolimus pharmacogenetics: the CYP3A5\u22171 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians","volume":"79","author":"Macphee","year":"2005","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.ajt.2026.07.031_bib9","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/ajt.15385","article-title":"Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: a comparison of four ancestry groups","volume":"19","author":"Oetting","year":"2019","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2026.07.031_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FTD.0b013e3181e06818","article-title":"Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients","volume":"32","author":"Kuypers","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.ajt.2026.07.031_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","article-title":"Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients","volume":"71","author":"Trofe-Clark","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ajt.2026.07.031_bib12","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.923278","article-title":"Effect of concentration\/dose ratio in de novo kidney transplant recipients receiving LCP-tacrolimus or immediate-release tacrolimus: post hoc analysis of a phase 3 clinical trial","volume":"25","author":"Suwelack","year":"2020","journal-title":"Ann Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2026.07.031_bib13","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.ajkd.2015.10.024","article-title":"Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial","volume":"67","author":"Rostaing","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.ajt.2026.07.031_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ajt.13935","article-title":"A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study","volume":"17","author":"Tremblay","year":"2017","journal-title":"Am J Transplant"},{"issue":"20","key":"10.1016\/j.ajt.2026.07.031_bib15","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.3390\/jcm13206241","article-title":"Renal allograft function and the tacrolimus C\/D ratio: insights from a prospective study on MeltDose tacrolimus","volume":"13","author":"D\u0119bska-\u015alizie\u0144","year":"2024","journal-title":"J Clin Med"},{"issue":"8Suppl 1","key":"10.1016\/j.ajt.2026.07.031_bib16","article-title":"Final results of the protection of renal function after conversion of fast IR-Tac metabolizers to envarsus study (the protect RENvarsus study) [abstract]","volume":"25","author":"Th\u00f6lking","year":"2025","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2026.07.031_bib17","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/cts.13206","article-title":"A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients","volume":"15","author":"Bunthof","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"11","key":"10.1016\/j.ajt.2026.07.031_bib18","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/tri.12798","article-title":"A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation","volume":"29","author":"Shuker","year":"2016","journal-title":"Transpl Int"},{"issue":"8","key":"10.1016\/j.ajt.2026.07.031_bib19","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1097\/TP.0000000000001796","article-title":"High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation","volume":"101","author":"Egeland","year":"2017","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ajt.2026.07.031_bib20","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/TP.0000000000002920","article-title":"The TOMATO study (tacrolimus metabolization in kidney transplantation): impact of the concentration-dose ratio on death-censored graft survival","volume":"104","author":"Jouve","year":"2020","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.ajt.2026.07.031_bib21","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1007\/s00467-025-06872-5","article-title":"Association of intrapatient tacrolimus variability and concentration-to-dose ratio with outcomes in pediatric kidney transplantation","volume":"40","author":"Baghai Arassi","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ajt.2026.07.031_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/srep32273","article-title":"Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation","volume":"6","author":"Th\u00f6lking","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ajt.2026.07.031_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95201-5","article-title":"Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation","volume":"11","author":"Th\u00f6lking","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ajt.2026.07.031_bib24","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1681\/ASN.2020081215","article-title":"Exploring the complexity of death-censored kidney allograft failure","volume":"32","author":"Mayrdorfer","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ajt.2026.07.031_bib25","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/ndt\/gfac327","article-title":"A single centre in-depth analysis of death with a functioning kidney graft and reasons for overall graft failure","volume":"38","author":"Mayrdorfer","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ajt.2026.07.031_bib26","article-title":"Hidden in plain sight: low tacrolimus metabolism doubles kidney transplant failure and drives infection related mortality","volume":"38","author":"S\u00fcsal","year":"2025","journal-title":"Transpl Int."},{"issue":"8","key":"10.1016\/j.ajt.2026.07.031_bib27","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/phar.2300","article-title":"Tacrolimus concentration-to-dose ratios in kidney transplant recipients and relationship to clinical outcomes","volume":"39","author":"Bartlett","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.ajt.2026.07.031_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/jcpt.13533","article-title":"Beneficial effects of Wuzhi capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes","volume":"47","author":"Kou","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"10.1016\/j.ajt.2026.07.031_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40262-020-00955-2","article-title":"Clinical impact of the adaptation of initial tacrolimus dosing to the CYP3A5 genotype after kidney transplantation: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Yang","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.ajt.2026.07.031_bib30","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/jcm14082542","article-title":"Optimization of the tacrolimus concentration-to-dose ratio cut-off value to define metabolism groups","volume":"14","author":"Th\u00f6lking","year":"2025","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ajt.2026.07.031_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/FTD.0b013e318285e779","article-title":"Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure","volume":"35","author":"Saint-Marcoux","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.ajt.2026.07.031_bib32","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/TP.0000000000004405","article-title":"Can the area under the curve\/trough level ratio be used to optimize tacrolimus individual dose adjustment?","volume":"107","author":"Woillard","year":"2023","journal-title":"Transplantation"},{"issue":"15\u201316","key":"10.1016\/j.ajt.2026.07.031_bib33","article-title":"Determination of tacrolimus in human whole blood in kidney transplant recipients using a rapid and specific LC-MS\/MS method","volume":"37","author":"Hieu","year":"2023","journal-title":"J Clin Lab Anal"},{"issue":"9","key":"10.1016\/j.ajt.2026.07.031_bib34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40262-025-01533-0","article-title":"A population pharmacokinetic model and dosing algorithm to guide the tacrolimus starting and follow-up dose in living and deceased donor kidney transplant recipients","volume":"64","author":"Francke","year":"2025","journal-title":"Clin Pharmacokinet"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526026961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526026961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:28:15Z","timestamp":1787257695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613526026961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"alternative-id":["S1600613526026961"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2026.07.031","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond trough levels: Tacrolimus dose requirements and individualized monitoring in kidney transplantation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2026.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}